Joseph Domachowske: Phase III MELODY and phase IIb trials investigating nirsevimab for the treatment of respiratory syncytial virus

Following the recent results from the pivotal Phase III MELODY and Phase IIb trials of nirsevimab in the treatment of respiratory syncytial virus, we were delighted to speak with Dr. Joseph Domachowske (Upstate University Hospital, Syracuse, NY, USA) to discuss the efficacy and safety of nirsevimab in the MELODY clinical trials and if approved, when and to whom will nirsevimab be administered.

Questions

1. What were the MELODY clinical trials and what did they teach us about the efficacy and safety of nirsevimab in infants? (00:15)
2. What have we learned from the current analyses of the MELODY clinical trial data? (02:17)
3. If approved, when and to whom will nirsevimab be administered? (02:58)

Disclosures: Joseph Domachowske discloses grant/research support from AstraZeneca.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.